Search

Displaying results 3021 - 3030 of 10000 in total
  1. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … progression on at least one line of endocrine therapy.

  2. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

    Mixtures: OB Complete 400, Se-Vate 21/7
  3. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, 1996. … It is a lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit which yields an injection.

  4. Target

    Mitogen-activated protein kinase kinase kinase 10

    go.drugbank.com/bio_entities/BE0009462
    TargetHumans

    Activates the JUN N-terminal pathway

    Polypeptides: Mitogen-activated protein kinase kinase kinase 10
  5. Target

    Tumor necrosis factor ligand superfamily member 10

    go.drugbank.com/bio_entities/BE0010497
    TargetHumans

    Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the d...

    Polypeptides: Tumor necrosis factor ligand superfamily member 10
  6. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

  7. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.

  8. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  9. Drug

    Diacetyl benzoyl lathyrol

    go.drugbank.com/drugs/DB11260
    Approved

    It is also reported to be a skin conditioning agent.

    Mixtures: The History Of Whoo Gongjinhyang Mi Luxury Bb
  10. Drug

    Rislenemdaz

    go.drugbank.com/drugs/DB12063
    Investigational

    Mk 0657 has been used in trials studying the treatment of Major Depressive Disorder.